Artiva BiotherapeuticsARTV +2.44%12 PB Ratio is 2.71 as of Jul. 13, 2026, which is 367% above its 10-year median of 0.58. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,231 Biotechnology companies, Artiva Biotherapeutics ranks better than 53.05% on this metric.
Artiva Biotherapeutics Inc stock PB Ratio (=2.71) is close to 2-year high of 2.71.
The historical rank and industry rank for Artiva Biotherapeutics's PB Ratio or its related term are showing as below:
ARTV'
s PB Ratio Range Over the Past 10 Years
Min: 0.19 Med: 0.58 Max: 2.71
Current: 2.71
During the past 7 years, Artiva Biotherapeutics's highest PB Ratio was 2.71. The lowest was 0.19. And the median was 0.58.
ARTV's PB Ratio is ranked better than 53.05% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs ARTV: 2.71
During the past 12 months, Artiva Biotherapeutics's average Book Value Per Share Growth Rate was -48.70% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Artiva Biotherapeutics was -95.90% per year. The lowest was -95.90% per year. And the median was -95.90% per year.
Back to Basics: PB Ratio
Artiva Biotherapeutics (NAS:ARTV) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Artiva Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artiva Biotherapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Artiva Biotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Artiva Biotherapeutics (ARTV) has a PB Ratio of 2.71 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Artiva Biotherapeutics and its competitors. This is 367% above median its historical median of 0.58. Over the past decade, Artiva Biotherapeutics' PB Ratio has ranged from 0.19 to 2.71. According to the industry distribution chart, Artiva Biotherapeutics ranks #578 out of 1231 companies in the Biotechnology industry, placing it in the top 47%.
Is Artiva Biotherapeutics' PB Ratio too high?
Artiva Biotherapeutics' current PB Ratio of 2.71 is 367% above median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 2.71. The Biotechnology industry median PB Ratio is 2.93. Artiva Biotherapeutics' value of 2.71 is 7.5% below this industry median. Based on the distribution chart, Artiva Biotherapeutics ranks #578 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' PB Ratio compare to OVID and INDP?
According to the Biotechnology industry distribution chart, Artiva Biotherapeutics ranks #578 out of 1231 companies for PB Ratio. This puts Artiva Biotherapeutics in the upper half of its industry. The industry median PB Ratio is 2.93. Artiva Biotherapeutics' value of 2.71 is 7.5% below this benchmark. Historically, Artiva Biotherapeutics' own PB Ratio has ranged from 0.19 to 2.71 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 2.93, Artiva Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artiva Biotherapeutics's current PB Ratio of 2.71 is 7.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Artiva Biotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artiva Biotherapeutics's current PB Ratio is 2.71, which is 367% above median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current PB Ratio of 2.71. The current PB Ratio is 2.71, which is 367% above median its 10-year median of 0.58 and 7.5% below the Biotechnology industry median of 2.93. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current PB Ratio is 2.71 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score
Get the complete analysis for ARTV
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTV has been successfully added to your 
